These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 4073928)

  • 21. [Antitumor effect of etoposide and its analogs].
    Kuramochi H; Okamoto K; Nishikawa K; Nagamine S; Takahashi K
    Gan To Kagaku Ryoho; 1985 Nov; 12(11):2196-201. PubMed ID: 4062319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
    Sirotnak FM; Otter GM; Schmid FA
    Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal treatment schedule and antitumor spectrum of 4-carbamoylimidazolium 5-olate (SM-108) in murine tumors.
    Yoshida N; Nakamura M; Fukui M; Morisada S; Ogino S; Inaba M; Tsukagoshi S; Sakurai Y
    Cancer Res; 1983 Dec; 43(12 Pt 1):5851-6. PubMed ID: 6640536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
    Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
    Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antitumor effect of FU-O-G, new antitumor agent, following long term administration].
    Mizuno H; Inomata T; Umezawa T; Shimizu F; Arakawa M
    Gan To Kagaku Ryoho; 1984 Sep; 11(9):1848-54. PubMed ID: 6433807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Early phase II study of oral administration of etoposide for 21 consecutive days in patients with non-small-cell lung cancer].
    Hayasaka S; Kinuwaki E; Nakabayashi T; Saito R; Komatsu H; Nishikawa H; Ohizumi K; Shimizu T; Nakai Y; Niitani H
    Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Dec; 33(12):1367-1371. PubMed ID: 8821989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of oral etoposide in small cell carcinoma of the lung].
    Miyamoto H; Ito M; Araya Y; Takaoka K; Isobe H; Dosaka H; Kawakami Y; Shimizu T; Onodera S
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1244-7. PubMed ID: 6329103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day.
    Aydiner A; Koyuncu H; Tas F; Topuz E; Disci R
    Int J Clin Pharmacol Res; 2000; 20(1-2):21-30. PubMed ID: 11146899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of unresectable non-small cell lung cancer (NSCLC) with carboplatin and chronic daily administration of oral etoposide].
    Hirabayashi M; Tanaka Y; Yoshida H; Nakagawa M; Kuno K
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):53-8. PubMed ID: 8291916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor effect to IL-12 administration into the portal vein on murine liver metastasis.
    Su W; Kitagawa T; Ito T; Oyama T; Lee CM; Kim YK; Matsuda H
    J Hepatobiliary Pancreat Surg; 2002; 9(4):503-10. PubMed ID: 12483274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etoposide by oral route in the treatment of unresectable non-small cell lung cancer.
    Scagliotti G; Lodico D; Gozzelino F; Pescetti G
    Chemioterapia; 1984 Oct; 3(5):324-6. PubMed ID: 6532545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
    Holm B; Sehested M; Jensen PB
    Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Toxicologic study and experimental antitumor activity of rubidomycin (13,057 R.P.)].
    Maral R; Bourat G; Ducrot R; Fournel J; Ganter P; Julou L; Koenig F; Myon J; Pascal S; Pasquet J; Populaire P; de Ratuld Y; Werner GH
    Pathol Biol; 1967 Oct; 15(19):903-8. PubMed ID: 4296784
    [No Abstract]   [Full Text] [Related]  

  • 36. Antitumor activity of a new compound, ethyl O-[N-(p-carboxyphenyl)-carbamoyl]-mycophenolate, against various experimental tumors upon oral administration.
    Mitsui H; Matsuno T; Ogawa H; Shiio T; Yugari Y; Tamura G
    Gan; 1981 Feb; 72(1):66-71. PubMed ID: 7274650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
    Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
    Dawson KM
    Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antitumor effects of a podophyllotoxin derivative, VP 16-213].
    Morita M; Haji A; Goto A; Hattori N; Hasegawa Y
    Nihon Yakurigaku Zasshi; 1986 Jan; 87(1):53-66. PubMed ID: 3957154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S; McGuire JJ; Rustum YM
    Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.